From Lipoproteins to Chondrocytes: A Brief Summary of the European Medicines Agency's Regulatory Guidelines for Advanced Therapy Medicinal Products

Abstract

Get full access to this article

View all access options for this article.

References

European Medicines Agency. [A] Committee for Advanced Therapies—focus on incentives for SMEs and strengthened interaction with stakeholders. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/02/news_detail_001717.jsp&mid=WC0b01ac058004d5c1. 2013 May .

European Medicines Agency. [B] Committee for Advanced Therapies rules of procedure. www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004761.pdf. 2013 May .

European Medicines Agency. [C] CAT monthly report of application procedures, guidelines and related documents on advanced therapies; April 2013 meeting. www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2013/04/WC500142879.pdf. 2013 May .

European Medicines Agency. [D] Assessment report for Glybera. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002145/WC500135476.pdf. 2013 May .

European Medicines Agency. [E] Assessment report for ChondroCelect. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000878/WC500026035.pdf. 2013 May .

European Medicines Agency. [F] MACI (matrix applied characterized autologous cultured chondrocytes): Summary of opinion. www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002522/WC500142496.pdf. 2013 May .

Maciulaitis

, D'Apote

, Buchanan

et al. 2012. Clinical development of advanced therapy medicinal products in Europe: Evidence that regulators must be proactive. Mol. Ther., 20:479–482.